KORU Medical reports preliminary Q4 revenue growth of 23%

KORU Medical Systems (NASDAQ: KRMD) reported preliminary fourth quarter 2025 net revenues of $10.9 million, representing 23% growth compared to the prior year period, according to a company statement.

The medical technology company's preliminary full year 2025 net revenues reached $41.1 million, marking 22% growth over the previous year. The company ended 2025 with a cash balance of $8.9 million and achieved positive cash flow from operations for the full year.

KORU Medical develops and manufactures subcutaneous infusion solutions, with its Freedom Infusion System used for drug delivery in home and clinical settings. The company recently submitted a 510(k) application to the FDA for clearance to use its Freedom Infusion System with Phesgo®, which would expand its applications into oncology treatments.

"We delivered strong fourth quarter results and enter 2026 with solid momentum, driven by continued strength in our core immunoglobulin business and growth in our recurring patient base," said Linda Tharby, President and CEO.

The company plans to release final fourth quarter and full year 2025 financial results along with 2026 guidance in early March 2026. The preliminary revenue figures are subject to adjustment following completion of review and audit procedures by the company's independent registered public accountants.

KORU Medical's Freedom System received its initial FDA clearance in 1994 and includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers along with related tubing and needle components.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Agilent Technologies filed for proposed debt offering
• General American Investors names new general counsel and CFO